GlassScriptPhysician profile
Scott F Lewis
NPI 1336368505
$19,612.94
in general payments reported to CMS, 2019-2025
36 companies · $3,382 in 2025
The $3,382 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,249 · 2020: $2,564 · 2021: $2,534 · 2022: $2,479 · 2023: $3,213 · 2024: $3,192 · 2025: $3,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,540 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,540.44 |
| Education | $246.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,376.39 | 2019-2025 | |
| Amgen INC. | $2,151.90 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Novartis Pharmaceuticals Corporation | $2,140.21 | 2019-2025 | |
| Janssen Biotech, INC. | $1,891.14 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,576.79 | 2019-2025 | |
| Ucb, INC. | $1,277.09 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,203.69 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $921.38 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $892.39 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $829.07 | 2020-2025 | Saphnelo, Tezspire |
| Alexion Pharmaceuticals, INC. | $531.73 | 2020-2025 | Strensiq |
| Lilly USA, LLC | $479.57 | 2019-2023 | Taltz |
| Mallinckrodt Hospital Products INC. | $282.52 | 2020-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $234.24 | 2023-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.68 | 2019-2025 | Cyltezo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $196.71 | 2019-2021 | |
| Radius Health, INC. | $184.42 | 2019-2024 | Tymlos |
| Sobi, INC | $152.30 | 2019-2025 | |
| Celgene Corporation | $140.01 | 2019-2021 | |
| Genzyme Corporation | $132.65 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $119.13 | 2022-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $119.09 | 2019-2020 | |
| Organon LLC | $93.92 | 2021-2025 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $79.26 | 2023 | Idacio |
| Sandoz INC. | $71.13 | 2023-2025 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $66.34 | 2019 | |
| Genentech USA, INC. | $59.51 | 2019-2023 | Actemra |
| Tersera Therapeutics LLC | $52.81 | 2023-2025 | Quzyttir |
| Nuvasive, INC. | $43.84 | 2022 | |
| Kyowa Kirin, INC. | $23.15 | 2025 | |
| Almatica Pharma LLC | $19.15 | 2024 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $17.56 | 2020 | |
| Orthogenrx INC. | $14.27 | 2019 | |
| Ascend Therapeutics US, LLC | $12.26 | 2021 | |
| Depuy Synthes Sales INC. | $11.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.